Can-Fite BioPharma (CANF) Short Interest Ratio & Short Volume $0.53 -0.04 (-6.63%) Closing price 10/10/2025 03:58 PM EasternExtended Trading$0.53 0.00 (-0.19%) As of 10/10/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Can-Fite BioPharma Short Interest DataCan-Fite BioPharma (CANF) has a short interest of 102,500 shares. This marks a -42.74% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.5, indicating that it would take 0.5 days of the average trading volume of 205,852 shares to cover all short positions.Current Short Interest102,500 sharesPrevious Short Interest179,000 sharesChange Vs. Previous Month-42.74%Dollar Volume Sold Short$66.22 thousandShort Interest Ratio0.5 Days to CoverLast Record DateSeptember 15, 2025Outstanding Shares3,540,000 sharesPercentage of Shares Shorted2.90%Today's Trading Volume316,232 sharesAverage Trading Volume205,852 sharesToday's Volume Vs. Average154% Short Selling Can-Fite BioPharma? Sign up to receive the latest short interest report for Can-Fite BioPharma and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCANF Short Interest Over TimeCANF Days to Cover Over TimeCANF Percentage of Float Shorted Over Time Can-Fite BioPharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 9/15/2025102,500 shares $66.22 thousand -42.7%N/A0.5 $0.65 8/31/2025179,000 shares $113.02 thousand +40.5%5.1%0.9 $0.63 8/15/2025127,400 shares $84.21 thousand -64.5%N/A0.7 $0.66 7/31/2025358,500 shares $240.16 thousand +283.0%10.1%2 $0.67 7/15/202593,600 shares $97.81 thousand -29.3%N/A0.8 $1.05 6/30/2025132,400 shares $139.02 thousand +353.4%3.7%0.6 $1.05 6/15/202529,200 shares $31.24 thousand -62.3%0.8%0.1 $1.07 5/31/202577,500 shares $83.31 thousand -47.2%2.2%0.3 $1.08 5/15/2025146,700 shares $153.30 thousand -52.4%N/A0.5 $1.05 4/30/2025308,000 shares $335.72 thousand -40.0%N/A1.1 $1.09 Get the Latest News and Ratings for CANF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter. 4/15/2025512,900 shares $646.25 thousand +35.4%N/A1.8 $1.26 3/14/2025204,400 shares $333.17 thousand -20.1%N/A1 $1.63 2/28/2025255,900 shares $450.38 thousand +44.0%N/A0.6 $1.76 2/14/2025177,700 shares $270.99 thousand -23.2%N/A0.4 $1.53 1/31/2025231,400 shares $348.03 thousand -8.9%N/A0.5 $1.50 1/15/2025254,000 shares $403.86 thousand -2.3%N/A0.6 $1.59 6/15/202362,200 shares $194.06 thousand -1.0%N/A1.1 $3.12 5/31/202362,800 shares $162.02 thousand -32.7%N/A1.1 $2.58 5/15/202393,300 shares $0.00 +311.0%N/A1.6 $0.00 4/30/202322,700 shares $0.00 -59.6%N/A0.3 $0.00 4/15/202356,200 shares $0.00 +43.4%N/A0.6 $0.00 3/31/202339,200 shares $89.77 thousand -26.5%N/A0.5 $2.29 3/15/202353,300 shares $0.00 +33.3%N/A0.7 $0.00 2/28/202340,000 shares $0.00 +4.2%N/A0.6 $0.00 2/15/202338,400 shares $0.00 -52.9%N/A0.6 $0.00 1/31/202381,600 shares $0.00 +91.1%N/A1.6 $0.00 1/15/202342,700 shares $0.00 -11.6%N/A1.1 $0.00 12/30/202248,300 shares $0.00 -82.9%N/A3.8 $0.00 12/15/2022282,700 shares $0.00 -19.6%N/A3.8 $0.00 11/30/2022351,500 shares $0.00 -7.5%N/A5.1 $0.00 11/15/2022379,900 shares $0.00 -9.7%N/A4.8 $0.00 10/31/2022420,700 shares $0.00 -5.0%N/A3.5 $0.00 10/15/2022442,900 shares $0.00 -6.9%N/A3.9 $0.00 9/30/2022475,600 shares $0.00 +1.1%N/A3.7 $0.00 9/15/2022470,400 shares $0.00 -7.2%N/A1.1 $0.00 8/31/2022506,600 shares $0.00 -5.9%N/A1.2 $0.00 8/15/2022538,500 shares $0.00 -8.2%N/A1.3 $0.00 7/31/2022586,400 shares $0.00 -10.6%N/A1.5 $0.00 7/15/2022655,700 shares $0.00 +68.5%N/A1.7 $0.00 6/30/2022389,100 shares $357.97 thousand +19.8%N/A1 $0.92 6/15/2022324,800 shares $0.00 -15.7%N/A2.3 $0.00 5/31/2022385,200 shares $0.00 -14.2%N/A2.6 $0.00 5/15/2022448,700 shares $0.00 -6.5%N/A2.2 $0.00 4/30/2022479,700 shares $0.00 -13.9%N/A2.2 $0.00 4/15/2022557,000 shares $0.00 -27.7%N/A2.1 $0.00 3/31/2022770,100 shares $0.00 +6.5%N/A2.3 $0.00 3/15/2022722,800 shares $0.00 -11.8%N/A0.2 $0.00 2/28/2022819,200 shares $0.00 +9.2%N/A0.2 $0.00 2/15/2022750,000 shares $0.00 -20.7%N/A0.2 $0.00 1/31/2022946,000 shares $0.00 -19.8%N/A0.2 $0.00 1/15/20221,180,000 shares $0.00 -73.5%N/A0.3 $0.00 12/31/20214,460,000 shares $0.00 +1,231.7%N/A1.2 $0.00 12/15/2021334,900 shares $0.00 -18.8%N/A0.1 $0.00 11/30/2021412,600 shares $0.00 +54.2%N/A1.9 $0.00 11/15/2021267,500 shares $0.00 -15.2%N/A1.3 $0.00 10/29/2021315,400 shares $479.41 thousand +54.3%N/A1.8 $1.52 10/15/2021204,400 shares $0.00 +5.4%N/A1.4 $0.00 9/30/2021193,900 shares $0.00 +25.0%N/A1.3 $0.00 9/15/2021155,100 shares $0.00 -11.5%N/A0.9 $0.00 8/31/2021175,300 shares $0.00 -29.7%N/A0.5 $0.00 8/13/2021249,300 shares $0.00 +10.3%N/A0.7 $0.00 7/30/2021226,100 shares $0.00 -29.8%N/A0.6 $0.00 7/15/2021322,200 shares $0.00 -5.7%N/A0.8 $0.00 6/30/2021341,500 shares $0.00 +0.7%N/A0.9 $0.00 6/15/2021339,300 shares $0.00 +12.9%N/A0.8 $0.00 5/28/2021300,500 shares $0.00 -35.4%N/A0.1 $0.00 5/14/2021465,300 shares $0.00 -14.2%N/A0.1 $0.00 4/30/2021542,400 shares $0.00 -23.7%N/A0.1 $0.00 4/15/2021711,200 shares $1.51 million -20.6%N/A0.2 $2.12 3/31/2021895,200 shares $2.03 million +187.5%N/A0.2 $2.27 3/15/2021311,400 shares $716.22 thousand -7.2%N/A0.1 $2.30 2/26/2021335,700 shares $772.11 thousand -37.5%N/A0.3 $2.30 2/12/2021537,200 shares $1.04 million +56.1%N/A0.5 $1.93 1/29/2021344,100 shares $812.08 thousand +23.3%N/A0.5 $2.36 1/15/2021279,000 shares $669.60 thousand -3.8%N/A0.6 $2.40 12/31/2020289,900 shares $530.52 thousand +13.5%N/A0.6 $1.83 12/15/2020255,400 shares $503.14 thousand -14.9%N/A0.6 $1.97 11/30/2020300,000 shares $564 thousand -13.1%N/A0.8 $1.88 11/15/2020345,200 shares $626.54 thousand +0.5%N/A0.9 $1.82 10/30/2020343,600 shares $601.30 thousand +4.9%N/A0.7 $1.75 10/15/2020327,600 shares $668.30 thousand -1.7%N/A0.5 $2.04 CANF Short Interest - Frequently Asked Questions What is Can-Fite BioPharma's current short interest? Short interest is the volume of Can-Fite BioPharma shares that have been sold short but have not yet been closed out or covered. As of September 15th, investors have sold 102,500 shares of CANF short. Learn More on Can-Fite BioPharma's current short interest. Is Can-Fite BioPharma's short interest increasing or decreasing? Can-Fite BioPharma saw a decline in short interest in September. As of September 15th, there was short interest totaling 102,500 shares, a decline of 42.7% from the previous total of 179,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Can-Fite BioPharma's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Can-Fite BioPharma: Qualigen Therapeutics, Inc. (2.53%), TNF Pharmaceuticals, Inc. (18.31%), Creative Medical Technology Holdings, Inc. (3.97%), Aprea Therapeutics, Inc. (1.68%), TransCode Therapeutics Inc. (7.04%), VYNE Therapeutics Inc. (4.59%), VivoSim Labs, Inc. (8.63%), BioCardia, Inc. (2.65%), Palisade Bio, Inc. (5.46%), Synaptogenix, Inc. (12.63%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Corporation ($8.81 billion), Canadian Natural Resources Limited ($5.82 billion), Reddit Inc. ($5.19 billion), Coinbase Global, Inc. ($4.52 billion), Robinhood Markets, Inc. ($4.30 billion), Charter Communications, Inc. ($3.75 billion), CoreWeave Inc. ($3.66 billion), Seagate Technology Holdings PLC ($3.57 billion), Live Nation Entertainment, Inc. ($3.33 billion), and Rocket Lab Corporation ($3.26 billion). View all of the most shorted stocks. What does it mean to sell short Can-Fite BioPharma stock? Short selling CANF is an investing strategy that aims to generate trading profit from Can-Fite BioPharma as its price is falling. CANF shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Can-Fite BioPharma? A short squeeze for Can-Fite BioPharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CANF, which in turn drives the price of the stock up even further. How often is Can-Fite BioPharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CANF, twice per month. The most recent reporting period available is September, 15 2025. More Short Interest Resources from MarketBeat Related Companies QLGN Short Interest Data TNFA Short Interest Data CELZ Short Interest Data APRE Short Interest Data RNAZ Short Interest Data VYNE Short Interest Data VIVS Short Interest Data BCDA Short Interest Data PALI Short Interest Data SNPX Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NYSE:CANF) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
